Article Figures & Data
Figures
- Figure 1.
Course of patients’ body temperature: maximum temperature in 1 day was monitored every day before and after infliximab infusion. Eighteen patients showed rapid decreases of fever within 24 hours after infliximab infusion. However, fluctuations of body temperature were noted in 2 patients. PE: plasma exchange.
- Figure 2.
Clinical data results. A. Symptoms: 18 patients with 5 or 6 major symptoms of Kawasaki disease at enrollment showed gradual decreases of these symptoms within 3 days after infliximab administration. B. White blood cell (WBC) counts: treatment resulted in rapid decreases of WBC within 2 to 3 days in those who responded to infliximab, assessed by fever and clinical symptoms. C. C-reactive protein (CRP): treatment provided rapid decreases of CRP within 2 to 3 days in those who were responders to infliximab, assessed by fever and clinical symptoms.
Tables
- Table 1.
Baseline characteristics of patients with Kawasaki disease (KD). Data are mean (range) unless otherwise indicated.
Characteristic Age, yrs 4.6 (1.9–10.5) Sex, male/female 10/10 Fulfillment of KD criteria 5/6: 5 cases 6/6: 15 cases Day receiving initial IVIG 4.3 (3–6) Dose of initial IVIG, g/kg 3.6 (3–4) Other medications, no. cases ASA 12 Flurbiprofen 8 Ulinastatin 2 Symptoms of KD before IFX Fever, °C 39.1 (38.4–40.5) Bilateral bulbar conjunctival injection 20 cases Changes in lips and oral cavity 20 cases Cervical lymphadenopathy 20 cases Polymorphous exanthema 15 cases Change in extremities 20 cases Laboratory findings before IFX White blood cell count, per μl 17,304 (8,400–30,600) Neutrophil count, % 75.6 (50.5–91.7) Platelet count, (× 104/μl) 43.0 (18.9–76.1) Serum albumin, g/dl 2.30 (1.6–3.1) C-reactive protein, mg/dl 14.8 (5.0–36.8) Coronary abnormalities 20 cases -
IVIG: intravenous immunoglobulin; IFX: infliximab; ASA: acetylsalicylic acid.
-
